ATE276271T1 - Rekombinantes virus - Google Patents
Rekombinantes virusInfo
- Publication number
- ATE276271T1 ATE276271T1 AT99910559T AT99910559T ATE276271T1 AT E276271 T1 ATE276271 T1 AT E276271T1 AT 99910559 T AT99910559 T AT 99910559T AT 99910559 T AT99910559 T AT 99910559T AT E276271 T1 ATE276271 T1 AT E276271T1
- Authority
- AT
- Austria
- Prior art keywords
- recombinant virus
- virus
- competant
- adenovirus
- mammal
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 241000710929 Alphavirus Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/193—Equine encephalomyelitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
- C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9806525.3A GB9806525D0 (en) | 1998-03-27 | 1998-03-27 | Recombinant virus |
| GBGB9825053.3A GB9825053D0 (en) | 1998-03-27 | 1998-11-17 | Recombinant virus |
| PCT/GB1999/000874 WO1999050292A1 (en) | 1998-03-27 | 1999-03-19 | Recombinant virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE276271T1 true ATE276271T1 (de) | 2004-10-15 |
Family
ID=26313370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99910559T ATE276271T1 (de) | 1998-03-27 | 1999-03-19 | Rekombinantes virus |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6565853B1 (de) |
| EP (1) | EP1064305B1 (de) |
| AT (1) | ATE276271T1 (de) |
| AU (1) | AU2948599A (de) |
| BR (1) | BR9909173A (de) |
| DE (1) | DE69920192T2 (de) |
| WO (1) | WO1999050292A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751226B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| CA2388337C (en) | 1999-10-22 | 2013-01-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| DK1282702T3 (da) | 2000-05-10 | 2007-04-02 | Sanofi Pasteur Ltd | Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf |
| US7309315B2 (en) * | 2002-09-06 | 2007-12-18 | Epoch Innovations, Ltd. | Apparatus, method and computer program product to facilitate ordinary visual perception via an early perceptual-motor extraction of relational information from a light stimuli array to trigger an overall visual-sensory motor integration in a subject |
| WO2008101349A1 (en) * | 2007-02-23 | 2008-08-28 | Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence | Recombinant viral vectors for prevention and protection against alphavirus infection |
| ES2544702T3 (es) * | 2008-07-17 | 2015-09-02 | Medigen, Inc. | Vacunas en forma de ADNi y métodos para utilizarlas |
| EP2440251A4 (de) | 2009-06-09 | 2013-01-16 | Defyrus Inc | Verabreichung von interferon zur prophylaxe gegen oder zur behandlung von krankheitserregenden infektionen |
| ES2921605T3 (es) | 2016-01-29 | 2022-08-30 | Bavarian Nordic As | Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante |
| JP6903120B2 (ja) * | 2016-07-15 | 2021-07-14 | エトゥビクス コーポレーション | アルファウイルスワクチン接種のための組成物及び方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
-
1999
- 1999-03-19 AT AT99910559T patent/ATE276271T1/de not_active IP Right Cessation
- 1999-03-19 US US09/646,970 patent/US6565853B1/en not_active Expired - Lifetime
- 1999-03-19 AU AU29485/99A patent/AU2948599A/en not_active Abandoned
- 1999-03-19 BR BR9909173-9A patent/BR9909173A/pt not_active Application Discontinuation
- 1999-03-19 WO PCT/GB1999/000874 patent/WO1999050292A1/en not_active Ceased
- 1999-03-19 DE DE69920192T patent/DE69920192T2/de not_active Expired - Lifetime
- 1999-03-19 EP EP99910559A patent/EP1064305B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6565853B1 (en) | 2003-05-20 |
| EP1064305B1 (de) | 2004-09-15 |
| EP1064305A1 (de) | 2001-01-03 |
| DE69920192D1 (de) | 2004-10-21 |
| WO1999050292A1 (en) | 1999-10-07 |
| AU2948599A (en) | 1999-10-18 |
| DE69920192T2 (de) | 2005-09-29 |
| BR9909173A (pt) | 2000-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69233158D1 (de) | Gentechnologisch hergestellter stamm für impfstoffe | |
| FI971783A7 (fi) | Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä | |
| DK1007686T3 (da) | Tuberkulosevaccine | |
| DK0584266T3 (da) | Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf | |
| SE9003978D0 (sv) | Dna expressionssystem baserade paa ett virus replikon | |
| BR9708387A (pt) | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. | |
| IT8519888A0 (it) | Casco di sicurezza, in particolare casco contro le cadute, costituito dal guscio di casco e da una parte supplementare (visiera o scudo)applicata ad innesto al guscio di casco. | |
| DE69332831T2 (de) | Rekombinanter schweinepocken-virus | |
| DE69920192D1 (de) | Rekombinantes virus | |
| AP2000001841A0 (en) | Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection. | |
| BR9202024A (pt) | Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo | |
| DE69704180D1 (de) | Antivirusverbindungen | |
| DE69703672D1 (de) | Antivirusverbindungen | |
| DE69705582D1 (de) | Antivirusverbindungen | |
| DE69704229D1 (de) | Antivirusverbindungen | |
| FI872635A0 (fi) | Nya polypeptider, deras framstaellning och anvaendning. | |
| OA09653A (en) | Rubella peptides | |
| BR0010222A (pt) | Vetores de expressão viral | |
| NO20023010L (no) | Forbedring av nukleinsyre-vaksinering | |
| CA2105277A1 (en) | Genetically engineered vaccine strain | |
| AR024989A1 (es) | Medios de transformacion de hongos y uso de los mismos para la produccion de proteinas heterologas. | |
| DE69705583D1 (de) | Antivirusverbindungen | |
| DK0675962T3 (da) | Syntetiske herpessimplexviruspromotore | |
| AR014784A1 (es) | Un acido nucleico que codifica un polipeptido que produce una respuesta protectora inmune contra un alfa-virus, una vacuna que lo comprende, su uso en la preparacion de medicamentos, un mutante de dicho alfavirus, un virus vaccinia y un plásmido | |
| CA2558659A1 (en) | Genetically engineered canary poxvirus-based vaccine strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |